NRX Pharmaceuticals Inc (NRXP) Stock is looking to regain its victory

Historical Earnings Surprises and Revenue Forecasts

Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.07 during the last quarter as opposed to a consensus estimate of -$0.11, which indicates the company beat its estimate by $0.04, which implies that the company surprised the market by 36.40%. It appears that the average earnings per share estimate for the current quarter (ending in Dec 2023) is -$0.07. This is an average of 3 analysts’ earnings, where the high earnings per share estimate is -$0.05 and the low earnings per share estimate is -$0.08.

The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated 35.09% within the last five trades and 14.67% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 65.16% in the last 6 months and 43.86% was added to its value over the previous 3 months. NRXP stock is trading at a margin of 24.89%, 27.62% and 25.93% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


As of the close of trading, NRXP deals in the Healthcare domain. The stock is trading -57.33 percent below its 52-week high and 131.67 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -37.28. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does NRX Pharmaceuticals Inc’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at 0.00 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $43.61 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 33.38 percent of NRX Pharmaceuticals Inc shares are owned by insiders, and 4.60 percent are held by financial institutions. Hurvitz Chaim, the Director at NRX Pharmaceuticals Inc (NRXP) has bought 70,000 shares of firm on Aug 30 at a price of $0.29 against the total amount of $20125.0. In another inside trade, Gorovitz Aaron, Director of NRX Pharmaceuticals Inc (NASDAQ:NRXP) bought 35,000 shares of the firm on Aug 30 for a total worth of $11196.0 at a price of $0.32. An inside trade which took place on Aug 23, Chief Scientist of NRX Pharmaceuticals Inc Javitt Jonathan C bought 100,000 shares of firm against total price of $33000.0 at the cost of $0.33 per share.

Related Posts